News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SALVAT Seeks FDA Approval For its CETRAXAL Otic (ciprofloxacin otic) 0.2% Solution, For The Treatment Of External Otitis



10/19/2005 5:10:58 PM

BARCELONA, Spain--(BUSINESS WIRE)--April 26, 2005--SALVAT announce plans to file their CETRAXAL Otic solution, with its convenient, single-dispensing container (SDC) format, with the FDA. The efficacy and safety of the treatment has been assessed in a 630 patient clinical trial, which will be the basis for their application in the 2nd quarter of 2005. "We combined the advantages of a proven, effective antibiotic with a simple, accurate form of administration. The idea behind our product is to reduce unnecessary ingredients thus avoiding unexpected adverse reactions, especially problematic in the paediatric population.

Read at BioSpace.com


comments powered by Disqus
   
Otitis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES